A Phase I, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects
Phase of Trial: Phase I
Latest Information Update: 24 Apr 2018
At a glance
- Drugs Yifenidone (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Pharmacokinetics
- Sponsors Sunshine Lake Pharma
- 16 Apr 2018 Planned End Date changed from 15 May 2018 to 15 Aug 2018.
- 16 Apr 2018 Planned primary completion date changed from 15 Jan 2018 to 15 Jun 2018.
- 16 Apr 2018 Status changed from not yet recruiting to recruiting.